Roivant Sciences (ROIV) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Roivant Sciences (NASDAQ: ROIV):

• 8/10/2026 – Roivant Sciences had its price target raised by Citigroup Inc. from $42.00 to $46.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Roivant Sciences had its price target raised by HC Wainwright from $34.00 to $41.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Roivant Sciences had its price target raised by Guggenheim from $36.00 to $42.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Roivant Sciences had its “buy” rating reaffirmed by TD Cowen.
• 7/31/2026 – Roivant Sciences had its “neutral” rating reaffirmed by Bank of America Corporation.
• 7/29/2026 – Roivant Sciences was upgraded by Sanford C. Bernstein to “strong-buy”.

Insider Activity

In other news, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This trade represents a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 2,520,739 shares of company stock valued at $87,746,445. Corporate insiders own 8.80% of the company’s stock.

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.